Hibo H Abdi1, Carl H Backes1,2,3,4, Molly K Ball1,2,3, Maria M Talavera-Barber5, Mark A Klebanoff1,2,6,7, Sudarshan R Jadcherla1,2,3,8,9, Tahagod H Mohamed2,10, Jonathan L Slaughter11,12,13,14. 1. Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. 2. Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA. 3. Division of Neonatology, Nationwide Children's Hospital, Columbus, OH, USA. 4. The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA. 5. Avera Research Institute Center for Pediatric and Community Research, Avera McKenna Hospital and University Healtch Center, Sioux Falls, SD, USA. 6. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA. 7. Department of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio, USA. 8. Innovative Infant Feeding Disorders Research Program, Nationwide Children's Hospital, Columbus, OH, USA. 9. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. 10. Division of Nephrology, Nationwide Children's Hospital, Columbus, OH, USA. 11. Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. jonathan.slaughter@nationwidechildrens.org. 12. Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA. jonathan.slaughter@nationwidechildrens.org. 13. Division of Neonatology, Nationwide Children's Hospital, Columbus, OH, USA. jonathan.slaughter@nationwidechildrens.org. 14. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA. jonathan.slaughter@nationwidechildrens.org.
Abstract
OBJECTIVES: To identify the relationship between prophylactic indomethacin (PI) administration and (1) mortality and bronchopulmonary dysplasia (BPD) at 36-week postmenstrual age (PMA) (primary outcome), and (2) to evaluate for PI-associated acute kidney injury. STUDY DESIGN: Retrospective cohort investigation of 22-28 weeks gestation infants (N = 1167) who were admitted to Nationwide Children's Hospital on postnatal days 0-1 between May 2009 and September 2017 and survived ≥24-h postnatal. The associations of PI treatment with mortality or BPD, and other secondary outcomes, were evaluated via multivariable robust-error-variance Poisson regression. RESULTS: The adjusted risks of death or BPD (1.02, 95% CI: 0.83, 1.25), BPD (0.97, 95% CI: 0.77, 1.21), and death 1.33 (95% CI: 0.84, 2.10) by 36-week PMA were unchanged following PI treatment after multivariable adjustment. No changes in mean creatinine levels were detected in exposed versus unexposed infants to suggest PI-induced AKI. CONCLUSION: Prophylactic indomethacin treatment was unrelated to mortality or BPD outcomes.
OBJECTIVES: To identify the relationship between prophylactic indomethacin (PI) administration and (1) mortality and bronchopulmonary dysplasia (BPD) at 36-week postmenstrual age (PMA) (primary outcome), and (2) to evaluate for PI-associated acute kidney injury. STUDY DESIGN: Retrospective cohort investigation of 22-28 weeks gestation infants (N = 1167) who were admitted to Nationwide Children's Hospital on postnatal days 0-1 between May 2009 and September 2017 and survived ≥24-h postnatal. The associations of PI treatment with mortality or BPD, and other secondary outcomes, were evaluated via multivariable robust-error-variance Poisson regression. RESULTS: The adjusted risks of death or BPD (1.02, 95% CI: 0.83, 1.25), BPD (0.97, 95% CI: 0.77, 1.21), and death 1.33 (95% CI: 0.84, 2.10) by 36-week PMA were unchanged following PI treatment after multivariable adjustment. No changes in mean creatinine levels were detected in exposed versus unexposed infants to suggest PI-induced AKI. CONCLUSION: Prophylactic indomethacin treatment was unrelated to mortality or BPD outcomes.
Authors: B Schmidt; P Davis; D Moddemann; A Ohlsson; R S Roberts; S Saigal; A Solimano; M Vincer; L L Wright Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245
Authors: R J Couser; T B Ferrara; G B Wright; A K Cabalka; C G Schilling; R E Hoekstra; N R Payne Journal: J Pediatr Date: 1996-05 Impact factor: 4.406
Authors: Jonathan L Slaughter; Clifford L Cua; Jennifer L Notestine; Brian K Rivera; Laura Marzec; Erinn M Hade; Nathalie L Maitre; Mark A Klebanoff; Megan Ilgenfritz; Vi T Le; Dennis J Lewandowski; Carl H Backes Journal: BMC Pediatr Date: 2019-09-13 Impact factor: 2.125